Gene · 4837
Papers1,489
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 1,489
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| NNMT switches the proangiogenic phenotype of cancer-associated fibroblasts via epigenetically regulating ETS2/VEGFA axis. | Oncogene | 2024 | 39069579 | PubTator, text mining | PubMed |
| NAD+ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. | J Immunother Cancer | 2024 | 39067875 | PubTator, text mining | PubMed |
| Inhibition of NNMT enhances drug sensitivity in lung cancer cells through mediation of autophagy. | Front Pharmacol | 2024 | 39035994 | PubTator, text mining | PubMed |
| Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. | Sci Rep | 2024 | 38969654 | PubTator, text mining | PubMed |
| Nicotinamide N-Methyltransferase (NNMT): A New Hope for Treating Aging and Age-Related Conditions. | Metabolites | 2024 | 38921477 | PubTator, text mining | PubMed |
| Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome. | Front Pharmacol | 2024 | 38919254 | PubTator, text mining | PubMed |
| Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. | Cell Metab | 2024 | 38897198 | PubTator, text mining | PubMed |
| Circadian Rhythm Disruption in Hepatocellular Carcinoma Investigated by Integrated Analysis of Bulk and Single-Cell RNA Sequencing Data. | Int J Mol Sci | 2024 | 38891936 | PubTator, text mining | PubMed |
| [Retracted] Nicotinamide N‑methyltransferase promotes epithelial‑mesenchymal transition in gastric cancer cells by activating transforming growth factor‑β1 expression. | Oncol Lett | 2024 | 38872863 | PubTator, text mining | PubMed |
| Nicotinamide N-Methyltransferase (NNMT) is Involved in Gastric Adenocarcinoma Immune Infiltration by Driving Amino Acid Metabolism. | Nutr Cancer | 2024 | 38855943 | PubTator, text mining | PubMed |
| Pan-cancer analysis combined with experiments predicts NNMT as a therapeutic target for human cancers. | Discov Oncol | 2024 | 38809277 | PubTator, text mining | PubMed |
| Exploring the Relevance of Disulfidptosis to the Pathophysiology of Ulcerative Colitis by Bioinformatics Analysis. | J Inflamm Res | 2024 | 38737111 | PubTator, text mining | PubMed |
| Metabolic Signaling in Cancer Metastasis. | Cancer Discov | 2024 | 38592405 | PubTator, text mining | PubMed |
| CAF-associated genes putatively representing distinct prognosis by in silico landscape of stromal components of colon cancer. | PLoS One | 2024 | 38557819 | PubTator, text mining | PubMed |
| Gastric Cancer in the Era of Epigenetics. | Int J Mol Sci | 2024 | 38542354 | PubTator, text mining | PubMed |
| Gastric Cancer With the Increased Nicotinamide N-methyltransferase-positive Stromal Cells Includes Unfavorable Prognosis-related Cancer-associated Fibroblasts. | Anticancer Res | 2024 | 38537979 | PubTator, text mining | PubMed |
| Knockdown of nicotinamide N-methyltransferase suppresses proliferation, migration, and chemoresistance of Merkel cell carcinoma cells in vitro. | Hum Cell | 2024 | 38504052 | PubTator, text mining | PubMed |
| The integrate profiling of single-cell and spatial transcriptome RNA-seq reveals tumor heterogeneity, therapeutic targets, and prognostic subtypes in ccRCC. | Cancer Gene Ther | 2024 | 38480978 | PubTator, text mining | PubMed |
| Identification and validation of m6A-associated ferroptosis genes in renal clear cell carcinoma. | Cell Biol Int | 2024 | 38440906 | PubTator, text mining | PubMed |
| Targeting nicotinamide N-methyltransferase decreased aggressiveness of osteosarcoma cells. | Eur J Clin Invest | 2024 | 38426563 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4837/papers?page=8